Visualizing the invisible: New fluorescent DNA label reveals nanoscopic cancer features

Researchers have developed a new fluorescent label that gives a clearer picture of how DNA architecture is disrupted in cancer cells. The findings could improve cancer diagnoses for patients and classification of future cancer risk.
Published today in Science Advances, the study found that the DNA-binding dye performed well in processed clinical tissue samples and generated high-quality images via superresolution fluorescence microscopy.
“My lab is focused on developing microscopy techniques to visualize the invisible,” said senior author Yang Liu, Ph.D., associate professor of medicine and bioengineering at the University of Pittsburgh. “We are one of the first groups to explore the capabilities of superresolution microscopy in the clinical realm. Previously, we improved its throughput and robustness for analysis of clinical cancer samples. Now, we have a DNA dye that is easy to use, which solves another big problem in bringing this technology to patient care.”
Inside the cell’s nucleus, DNA strands are wound around proteins like beads on a string. Pathologists routinely use traditional light microscopes to visualize disruption to this DNA-protein complex, or chromatin, as a marker of cancer or precancerous lesions.
“Although we know that chromatin is changed at the molecular scale during cancer development, we haven’t been able to clearly see what those changes are. This has bothered me for more than 10 years,” said Liu, who is also a member of the UPMC Hillman Cancer Center. “To improve cancer diagnosis, we need tools to visualize nuclear structure at much greater resolution.”
In 2014, the Nobel Prize-winning invention of superresolution fluorescence microscopy was a major step towards making Liu’s vision reality. A molecule of interest is labelled with a special fluorescent dye that flashes on and off like a blinking star. Unlike traditional fluorescence microscopy, which uses labels that glow constantly, this approach involves switching on only a subset of the labels at each moment. When several images are overlayed, the complete picture can be reconstructed — at a much higher resolution than previously possible.

Read more →

Changing the standard of care for stage III melanoma surgery

For years, surgery for patients with stage III melanoma — melanoma that has spread to the lymph nodes — involved removing those lymph nodes along with the primary tumor. Known as completion lymph node dissection (CLND), the surgery was meant to ensure that no cancer remained after surgery.
More recently, however, cancer surgeons have discovered that CLND has the potential to cause more problems than it solves. In most cases, patients do better on immunotherapy alone than they do when their surgery involves removal of the lymph nodes, due to potential complications from lymph node surgery.
In a paper published in February in the Annals of Surgical Oncology, University of Colorado (CU) Cancer Center members Martin McCarter, MD, Camille Stewart, MD, Karl Lewis, MD, William Robinson, MD, Ana Gleisner, MD, PhD, and Rene Gonzalez, MD — along with CU School of Medicine resident Robert Torphy, MD, PhD — reviewed their patient data to determine if immunotherapy alone resulted in better outcomes than CLND.
“In the few years prior to immunotherapy being available, some surgical trials were done asking if regional node dissection by itself improves overall survival for the patients,” says McCarter, a professor of surgical oncology at the CU School of Medicine. “And the answer came back: no, it did not improve survival. That had been the standard forever, because we didn’t have other effective therapies, but once the definitive trials were done, we learned that CLND wasn’t helping, it wasn’t improving survival. Subsequent trials demonstrated that immunotherapy can improve survival in metastatic melanoma.”
Better outcomes with immunotherapy
For the study, Torphy, working with McCarter and the other researchers, looked at data on 90 patients who underwent sentinel lymph node biopsy (a procedure to determine if a skin melanoma has spread microscopically) only for stage III melanoma but did not undergo CLND. Of those patients, 56 received immunotherapy and 34 did not. Those who received immunotherapy had better rates of distant metastasis-free survival, meaning their cancer was less likely to come back.

Read more →

A new study relates liquid fructose intake to fatty liver disease

A high-fat diet is not enough to cause short-term fatty liver disease. However, if this diet is combined with the intake of beverages sweetened with liquid fructose, the accumulation of fats in the liver accelerates and hypertriglyceridemia — a cardiovascular risk factor — can appear.
This is explained in a study on a mouse experimental model, published in the journal Molecular Nutrition and Food Research and led by Professor Juan Carlos Laguna, from the Faculty of Pharmacy and Food Sciences, the Institute of Biomedicine of the University of Barcelona (IBUB) and the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre (CIBEROBN).
The study counts on the collaboration of the researchers Aleix Sala-Vila and Iolanda Lázaro, from the Hospital del Mar Medical Research Institute (IMIM), and José Rodríguez-Morató, from IMIM-Hospital del Mar and MELIS-Pompeu Fabra University, among other experts.
Fructose and lipid metabolism
Fructose is one of the most common sweeteners in the food industry. This simple sugar (monosaccharide) is industrially obtained from corn syrup, a product derived from this gramineae. With a great sweetener power and low production costs, fructose is used by the food industry to sweeten beverages, sauces and processed foods, despite the scientific evidence that associates it with metabolic diseases which are risk factors of cardiovascular pathologies.
According to the new study, the effect caused by fructose in the increase in the synthesis of fatty acids in the liver is more decisive than the external introduction of fats through the diet. “In high-fat diets which are supplemented with liquid fructose, this monosaccharide is able to induce an increase in the de novo lipogenesis — that is, the formation of fats through sugar — and an inhibition of the lipid oxidation in the liver,” says Professor Juan Carlos Laguna, from the Department of Pharmacology, Toxicology and Therapeutical Chemistry.

Read more →

Microneedle approach to address peanut allergy shows promise in mice

Treating peanut allergy with microneedles could significantly improve desensitization by directly targeting the allergen to the skin, providing greater protection from severe allergic reactions for millions of people, a new study suggests.
Investigators at Michigan Medicine, in collaboration with researchers from Moonlight Therapeutics, tested a dermal stamp containing peanut-coated microneedles on mice by applying it to the skin for five minutes once a week over five weeks. They compared that to mice receiving epicutaneous immunotherapy, which involves wearing a patch on the skin for 24 hours over the same time period.
The results, published in Immunotherapy, reveal mice that received the five weekly microneedle treatments had significant increased rates of desensitization to peanut allergy compared with EPIT, which required two months of treatment to achieve protection. The microneedle treatment success was achieved despite applying a dose of peanut protein 10-times lower than the dose delivered by EPIT.
“While our pre-clinical results are from studies in animal models, they demonstrate the potential for peanut microneedles to improve food allergen immunotherapy through the skin,” said Jessica O’Konek, Ph.D., senior author of the paper and research assistant professor at the Mary H. Weiser Food Allergy Center at Michigan Medicine. “Treatment options for food allergy are limited, so there is a lot of motivation for the development of novel therapeutics. It will be exciting to watch the clinical development of this technology,” she said.
Around 6 million Americans have a peanut allergy, with symptoms that can range from mild hives to potentially fatal anaphylactic reactions. Currently, orally administered immunotherapy is the only treatment for peanut allergy approved by the United States Food and Drug Administration. However, it requires that patients follow a strict long-term protocol for ingesting each dose.
EPIT has been demonstrated to be safe in clinical trials, but the treatment showed variability in efficacy. O’Konek believes this could be due to the barrier provided by the skin surface, which may limit the amount of allergen taken up by the body. Targeted delivery of peanut protein with microneedle patches may offer more controlled delivery of allergen.
“This is a very interesting technology that could provide a unique method to desensitize people with food allergies,” said James R. Baker, Jr., M.D., co-author of the paper and director of the Mary H. Weiser Food Allergy Center. “These successful animal results argue for further development of this platform.”
Additional authors include: Mary H. Weiser Food Allergy Center: Jeffrey Landers, Katarzyna Janczak; Akhilesh Kumar Shakya & Harvinder Singh Gill, Texas Tech University Department of Chemical Engineering; Vladimir Zarnitsyn & Samirkumar R. Patel, Moonlight Therapeutics, Inc.
The microneedle device used in the study was based on the proprietary treatment platform TASIS (Targeted Allergen-Specific Immunotherapy within the Skin) developed by Atlanta-based Moonlight Therapeutics.
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases under award numbers R42AI143011 and R01AI135197.
Gill and Shakya are co-inventors on a patent related to coated microneedles for allergen immunotherapy. Moonlight Therapeutics is pursuing this technology for developing microneedles for peanut and other food allergy immunotherapies. Gill and Shakya have equity in Moonlight Therapeutics. Patel and Zarnitsyn are employees of Moonlight Therapeutics and have equity in the company.
Story Source:
Materials provided by Michigan Medicine – University of Michigan. Original written by Noah Fromson. Note: Content may be edited for style and length.

Read more →

AI helped protect businesses from COVID-19 risks

A new study has found that artificial intelligence (AI) apps helped protect small and medium-sized businesses against many of the risks that emerged during the COVID-19 pandemic — yet only a quarter of small firms currently use them.
The research, undertaken by Anglia Ruskin University (ARU) and published in the journal Information Systems Frontiers, surveyed 317 small and medium sized firms based in London. The study found the use of AI-powered apps was associated with a 3.1% reduced risk to business during the pandemic.
The COVID-19 pandemic has created risks for economies and business operations, with customers stopping, reducing, or postponing purchases, thereby affecting supply chains and resulting in difficulties in sourcing alternative suppliers.
Business risks were defined by a 60-point scale developed by the International Labor Organization’s (ILO) that measures the pandemic’s impact on staffing, processes such as working patterns, reduced profits, and threats to partnerships.
AI software utilised by businesses include chatbots to allow swift interaction with customers, apps that identify damaging fake reviews, and apps that use algorithms to improve customer targeting based on their habits, social media activities and profiles, online activities, and past transactions.
The study found the use of AI apps to offer personalised shopping suggestions was associated with 2% lower business risks to profits caused by the COVID-19 pandemic. The use of AI apps to target audience online was associated with 1.2% lower overall business risk.
However, the research revealed that only 26% of small enterprises were utilising AI applications, considerably lower than the 70.4% of medium-sized businesses.
Lead author Professor Nick Drydakis, Director of the Centre for Pluralist Economics at Anglia Ruskin University, said: “SMEs can invest in AI technologies to track users’ habits and provide recommendations, improve customer’s purchasing decisions, search results, media communication, trade raise sales, improve organisational performance, and lower costs.
“AI can help SMEs to adapt to unprecedented conditions, meaning they can leverage technology to meet new types of demand, move at speed to pivot business operations, boost efficiency and reduce their business risks.
“We found that SMEs’ business risks caused by the COVID-19 pandemic declined with the use of AI applications across a ten-item scale including marketing, sales, communication, predictions, pricing and cash flow, fake reviews, cybersecurity, recruitment, and legal services.
“The outcomes proved true regardless of enterprise size, turnover, and years of operation, indicating that AI applications have helped SMEs to adapt to unprecedented conditions during the COVID-19 pandemic.
“It seems investment in AI apps could be a smart move for the three quarters of small businesses that do not currently utilise them.”

Read more →

New treatment to combat obesity and heart disease

An interdisciplinary research team at The University of Texas at San Antonio has successfully developed an innovative inhibitor that shows promise in fighting obesity and potentially preventing heart disease. Francis Yoshimoto, an assistant professor in the UTSA College of Sciences’ Department of Chemistry, is leading a team that developed an anti-obesity drug that blocks the effects of cytochrome P450 8B1, the enzyme linked to cholesterol absorption and obesity.
Yoshimoto collaborated with Eunhee Chung, an associate professor in the UTSA College of Health, Community and Policy’s Department of Kinesiology to test the new drug. After designing and synthesizing it, Yoshimoto sent test samples to Chung’s National Institutes of Health-funded laboratory, where she and her research team are conducting research on the effects of bioactive compounds — chemicals found in small amounts in plants and certain foods — and how exercise can be used to treat obesity and associated metabolic disorders.
Their research findings were published in the February 2022 issue of the scientific journal, Steroids.
“Growing up, I dreamed of helping my family members, who were affected by obesity and heart disease and other medical conditions,” Yoshimoto said. “This dream is now turning into a reality, as we have developed a small molecule that can be used to fight obesity, a problem seen in many families around the world.”
“As an exercise physiologist, I truly believe exercise is the best medicine to fight against noncommunicable diseases,” added Chung. “Unfortunately, the adherence to exercise is quite low, and the prevalence of obesity is continuously rising. Based on promising data, I have high hopes of further testing Dr. Yoshimoto’s inhibitor.”
UTSA’s drug has the potential to stop the activity of P450 8B1, the enzyme that creates cholic acid in the body. This inhibition, in turn, decreases cholesterol absorption. This process may hold the key to treating obesity-associated metabolic disorders and other diseases linked to obesity, such as heart disease and diabetes.
The team’s research included treating mice with the inhibitor drug for seven days. The result was a decrease in the levels of glucose in their blood — despite having been fed a high-fat and high-sucrose diet — without affects to their body weight. The results demonstrate how a P450 8B1 inhibitor could lead to a healthier metabolic profile and its potential could lead to developing a therapeutic strategy to treat obesity-associated insulin resistance.
Yoshimoto and Chung’s work is representative of UTSA’s mission to develop solutions for complex challenges that will improve the health and well-being of society. Creating a drug effective in preventing obesity could improve quality of life around the world.
According to the World Health Organization, 1.9 billion adults worldwide were overweight in 2016, and 650 million were classified as obese. Closer to home, one in every four deaths in the U.S. is due to heart disease, of which obesity is a major contributor. Locally, 71% of adults are overweight or obese, according to a recent report from the San Antonio Metropolitan Health District.
“These results show how our research in synthetic chemistry can significantly contribute to the well-being of society by treating obesity and heart disease,” Yoshimoto said.
Yoshimoto’s medicinal chemistry research was made possible by the Max and Minnie Tomerlin Voelcker Fund, which contributed $450k in 2019 to support anti-obesity research.
Chung’s research was supported by the National Institutes of Health [NIH, NIGMS, grant GM125603].
Story Source:
Materials provided by University of Texas at San Antonio. Note: Content may be edited for style and length.

Read more →

More alcohol, less brain: Association begins with an average of just one drink a day

Even light-to-moderate drinking is associated with harm to the brain, according to a new study. Researchers analyzed data from more than 36,000 adults that found a link between drinking and reduced brain volume that begins at an average consumption level of less than one alcohol unit a day — the equivalent of about half a beer — and rises with each additional drink.
The research, using a dataset of more than 36,000 adults, revealed that going from one to two drinks a day was linked with changes in the brain equivalent to aging two years. Heavier drinking was associated with an even greater toll. The science on heavy drinking and the brain is clear: The two don’t have a healthy relationship. People who drink heavily have alterations in brain structure and size that are associated with cognitive impairments.
But according to a new study, alcohol consumption even at levels most would consider modest — a few beers or glasses of wine a week — may also carry risks to the brain. An analysis of data from more than 36,000 adults, led by a team from the University of Pennsylvania, found that light-to-moderate alcohol consumption was associated with reductions in overall brain volume.
The link grew stronger the greater the level of alcohol consumption, the researchers showed. As an example, in 50-year-olds, as average drinking among individuals increases from one alcohol unit (about half a beer) a day to two units (a pint of beer or a glass of wine) there are associated changes in the brain equivalent to aging two years. Going from two to three alcohol units at the same age was like aging three and a half years. The team reported their findings in the journal Nature Communications.
“The fact that we have such a large sample size allows us to find subtle patterns, even between drinking the equivalent of half a beer and one beer a day,” says Gideon Nave, a corresponding author on the study and faculty member at Penn’s Wharton School. He collaborated with former postdoc and co-corresponding author Remi Daviet, now at the University of Wisconsin-Madison, and Perelman School of Medicine colleagues Reagan Wetherill — also a corresponding author on the study — and Henry Kranzler, as well as other researchers.
“These findings contrast with scientific and governmental guidelines on safe drinking limits,” says Kranzler, who directs the Penn Center for Studies of Addiction. “For example, although the National Institute on Alcohol Abuse and Alcoholism recommends that women consume an average of no more than one drink per day, recommended limits for men are twice that, an amount that exceeds the consumption level associated in the study with decreased brain volume,”
Ample research has examined the link between drinking and brain health, with ambiguous results. While strong evidence exists that heavy drinking causes changes in brain structure, including strong reductions in gray and white matter across the brain, other studies have suggested that moderate levels of alcohol consumption may not have an impact, or even that light drinking could benefit the brain in older adults.

Read more →

Henipavirus glycoprotein architecture suggests therapeutic strategies

Recent molecular findings offer new details on how Nipah and Hendra viruses attack cells, and the immune responses that try to counter this onslaught. The results point toward multi-pronged tactics to prevent and treat these deadly illnesses.
This research is reported today in Science as a First Release peer-reviewed paper, published rapidly online.
Both Nipah virus and Hendra virus are carried by bats native to certain parts of the world. These henipaviruses jump species and can infect many other mammals, including humans. The viruses cause brain inflammation and respiratory symptoms. People acquiring either of these diseases stand a 50% to 100% chance of succumbing.
There is a vaccine approved for use in horses and a modified version entered a human clinical trial.
Horses can spread Hendra, possibly contracted from eating bat-contaminated fruit, to their caretakers through saliva and nasal secretions. An experimental, but not yet approved, cross-reactive antibody expected to work against both Nipah and Hendra viruses has been given to fifteen people who had a high-risk exposure. This was done under emergency compassionate use guidelines. This antibody is in a clinical trial in Australia, where it has just completed the Phase 1 stage of testing. There are no approved vaccines or therapies for use in humans against these henipaviruses, other than supportive care in the limited hope that the patient can overcome the virus.
New attempts to design life-saving preventatives and treatments became even more urgent after a new strain of Hendra was discovered a few months ago. Outbreaks of Nipah virus have appeared nearly every year over the past two decades in Bangladesh. The disease also has been seen in India and the Philippines. Henipavirus antibodies have been detected in people and Pteropus bats in Africa. It’s estimated that 2 billion people live in the parts of the world where henipavirus spillovers from bats, or intermediary animal vectors, could be a threat.

Read more →

Review: “Empire of the Scalpel,” by Ira Rutkow

Ira Rutkow’s “Empire of the Scalpel” is by turns fascinating and ghastly.EMPIRE OF THE SCALPEL: The History of Surgery, by Ira RutkowI find it difficult to imagine being a surgeon in the conditions in which my predecessors had to work — gloveless, covered in blood, with patients physically tied down and screaming in pain, not to mention a postoperative mortality of almost 50 percent. And yet in “Empire of the Scalpel,” Ira Rutkow quotes the 18th-century English surgeon William Cheselden, who wrote of himself:“No one ever endured more anxiety and sickness before an operation, yet from the time that I began to operate, all uneasiness ceased … [I was] never ruffled or disconcerted and [my hand] … never trembled during an operation.”I can identify with this sentiment across the centuries, despite all the changes since Cheselden’s time. It expresses exactly what I and other surgeons — or “scalpel wielders,” as Rutkow calls us in his somewhat florid style — experience when operating. We have to make a strange transition as we enter the operating room — from caring about patients as fellow human beings to seeing them as objects, albeit living objects with anxious relatives waiting outside. It is a difficult balancing act between empathy and detachment, and the intense self-belief that surgery involves can lead us to become very fixed in our opinions. We feel threatened by any suggestion that there are better ways of doing things than the ways that have served us well for many years.Perhaps this explains why progress in surgery has sometimes been erratic. Rutkow quotes surgeons in the mid-19th century who argued against anesthesia on the outrageous grounds that pain was necessary for healing. But many others adopted anesthesia very quickly, including Robert Liston, a leading surgeon in London. In order to minimize the suffering of his un-anesthetized patients, he had perfected the art of amputating a leg in minutes. It is said — although this might be apocryphal — that he had once accidentally severed his assistant’s fingers along with the patient’s leg, both the assistant and the patient dying afterward from postoperative sepsis (as well as a spectator who died from shock).As Rutkow observes at the beginning of his book, it is a “reasonable certainty that no one in the industrialized world will escape having an illness for which effective treatment requires a surgical operation.” I myself would probably be blind in at least one eye (from retinal detachments), walk with a limp (from a complex ankle fracture) and possibly be dead (from urosepsis) if not for the help of my surgical colleagues. Yet until 150 years ago, as Rutkow explains, surgery was limited to the external parts of the human body, such as amputations for trauma. The only internal surgery was the occasional foray into the bladder for bladder stones and trepanning of the skull. Indeed, skulls have been found all over the planet, dating back thousands of years, with deliberately made holes that had healed over with new bone, meaning that the patient survived the procedure. But it is anybody’s guess as to whether the earliest trepanning was done to release a traumatic blood clot from inside the skull, or to release an evil spirit responsible for epilepsy or some similar, misunderstood disorder.As Rutkow writes, the emergence of surgery from its barbaric past rested on four pillars — the understanding of anatomy, the control of bleeding, anesthesia and antisepsis. The story, however, is not one of steady, rational progress. The surgeon Galen, working in the second century A.D., wrote extensively on anatomy; some of his experience came from treating wounded gladiators but much of it was based on dissecting animals, and was simply wrong with respect to human anatomy. His writings were passed down by the Andalusian physician Abu al-Qasim al-Zahrawi, among others, to become dogma in the Middle Ages.The first breakthrough came more than a thousand years later with the Renaissance, and the relaxation of taboos about dissecting the dead. The Flemish physician Andreas Vesalius, the greatest of the early anatomists, carried out his dissections on the corpses of executed criminals, often removed surreptitiously from the gallows at night. Surgeons such as Ambroise Paré in France, working on battlefield injuries, established ways of controlling bleeding — tying off blood vessels, for instance, rather than using red-hot irons and plunging the stump of an amputated limb into boiling oil.But the greatest change came in the mid-19th century, with the use of ether as an anesthetic, and Joseph Lister’s work on antisepsis. This was based on Louis Pasteur’s work showing that infection was caused by living microbes, and not (as had been previously thought) by smells and foul air. And yet, as the medical historian David Wootton has pointed out in his book “Bad Medicine,” the Swiss physician Paracelsus was using ether to anesthetize chickens in the 16th century and Antonie van Leeuwenhoek had discovered bacteria, using a microscope of his own making (although of rather an awkward design), in the 17th century. The German Hungarian obstetrician Ignaz Semmelweis showed that hand-washing made a massive difference to the incidence of fatal postnatal infections in women. This was 20 years before Lister’s and Pasteur’s work, yet Semmelweis was dismissed by his colleagues and he died in obscurity. The history of surgery, especially until the modern era, is as much about doctors’ innate conservatism as it is about innovation.It is, however, ultimately a history of triumphant progress — although not without dark episodes, such as the abuse of psychosurgery in the middle of the 20th century.Rutkow discusses at great length the evolution of surgery as a separate specialty, and the rivalry between surgeons and other medical practitioners. But even here, in the rather tedious detail, there are human stories. In 17th-century France, for instance, the granting of a royal charter to surgeons was accelerated by the successful operation on Louis XIV’s anal fistula by Charles-François Félix. Surgeons pride themselves on operating on celebrities — it marks their successful ascent of the professional ladder. But it comes at the price of considerable anxiety. I greatly admire Félix’s bravery, but he did spend six months practicing on less exalted patients before he felt able to tackle the royal anus.Rutkow is a surgeon, but freely admits he has always been more drawn to the history of surgery than surgery itself, and he confines his own surgical practice to relatively simple cases. Readers of the book looking for the blood and drama that is such a vital part of surgery will not find much of it. Instead, they will learn that the history of modern surgery is the history of the rise of the modern world, with all that has involved — not just science and technology but also politics, architecture, demographics and institutions. Rutkow includes some important chapters on the past prevalence of antisemitism in American medicine, and on the difficulties faced by members of other ethnic minorities and women in gaining entrance to the profession (a problem not confined to the United States). This has changed profoundly in recent years, but there is still progress to be made. It shows how the history of surgery is about so much more than just science and new surgical procedures. All human life is there.Henry Marsh is a neurosurgeon and the author of “Do No Harm” and “Admissions.”EMPIRE OF THE SCALPEL: The History of Surgery, by Ira Rutkow | Scribner | 381 pages | $29.99

Read more →

Resistance exercise may be superior to aerobic exercise for getting better ZZZs

Resistance exercise may be superior to aerobic exercise as a way to get better sleep, and sleep is important for cardiovascular health, according to preliminary research to be presented at the American Heart Association’s Epidemiology, Prevention, Lifestyle & Cardiometabolic Health Conference 2022. The meeting will be held in-person in Chicago and virtually Tuesday, March 1 — Friday, March 4, 2022, and offers the latest in population-based science related to the promotion of cardiovascular health and the prevention of heart disease and stroke.
“It is increasingly recognized that getting enough sleep, particularly high-quality sleep, is important for health including cardiovascular health. Unfortunately, more than a third of Americans don’t get enough sleep on a regular basis,” said study author Angelique Brellenthin, Ph.D., assistant professor of kinesiology at Iowa State University in Ames, Iowa. “Aerobic activity is often recommended to improve sleep, yet very little is known about the effects of resistance exercise versus aerobic exercise on sleep. The U.S. Department of Health and Human Services’ 2018 Physical Activity Guidelines Advisory Committee Scientific Report identified the need for more research into resistance exercise and sleep outcomes. Our study is one of the largest and longest exercise trials in a general adult population to directly compare the effects of different types of exercise on multiple sleep parameters.”
Previous research has confirmed that not getting enough sleep (the recommended amount for adults is seven to eight hours a day) or getting poor quality sleep increases risks for high blood pressure, elevated cholesterol and atherosclerosis, which happens when fatty deposits build up in arteries. Not getting enough sleep is linked to weight gain, diabetes and inflammation, all of which can worsen cardiovascular disease. Sleeping too much or too little also has been shown to increase the risk of stroke, heart attack and death.
For this study, researchers enrolled 386 adults who met the criteria for overweight or obesity, which was a body mass index from 25-40 kg/m². Participants were inactive and had elevated blood pressure, measuring from 120-139 mm Hg systolic (top number) and 80-89 mm Hg diastolic (bottom number). Participants were randomly assigned to a no-exercise group (for comparison) or one of three exercise groups (aerobic only, resistance only, or combined aerobic and resistance) for 12 months. Everyone in the exercise groups participated in supervised 60-minute sessions, three times a week, with the combination exercise group doing 30 minutes of aerobic and 30 minutes of resistance exercise.
The various workouts included: Aerobic exercise participants could choose among treadmills, upright or recumbent bikes or ellipticals for their aerobic modality during each session. Researchers monitored their heart rates to keep them continuously in the prescribed heart rate range for a moderate-to-vigorous intensity exercise. The resistance exercise group completed their sets and repetitions on 12 resistance machines to work all the major muscle groups in a session. The machines included leg press, chest press, lat pulldown, leg curl, leg extension, biceps curl, triceps pushdown, shoulder press, abdominal crunch, lower back extension, torso rotation and hip abduction. Participants performed three sets of 8 to 16 repetitions at 50-80% of their one-rep maximum. The combination group did 30 minutes of aerobic exercise at a moderate-to-vigorous intensity, and then two sets of 8 to 16 repetitions of resistance exercise on 9 machines instead of 12.Study participants completed a variety of assessments at the start and at 12 months including the self-reported Pittsburgh Sleep Quality Index (PSQI), which measures sleep quality. Researchers also measured sleep duration; sleep efficiency (how much time one is actually asleep divided by the total amount of time the individual is in bed); sleep latency (how much time it takes to fall asleep after getting into bed); and sleep disturbances (how frequently sleep is disturbed by things like being too hot or too cold, snoring or coughing, having to use the bathroom or having pain). Lower scores on the PSQI indicate better quality sleep, ranging from 0 for the best sleep to 21 as the worst possible sleep. Scores greater than five are considered “poor quality sleep.”
The study found: More than one third (35%) of study participants had poor quality sleep at the beginning of the study. Among the 42% of participants who were not getting at least 7 hours of sleep at the study’s start, sleep duration increased by an average of 40 minutes in 12 months for the resistance exercise group, compared to an increase of about 23 minutes in the aerobic exercise group, about 17 minutes in the combined exercise group and about 15 minutes in the control group. Sleep efficiency increased in the resistance exercise and combined exercise groups, but not in the aerobic exercise or no exercise group. Sleep latency decreased slightly, by 3 minutes, in the group assigned to resistance exercise only, with no notable change in latency in the other participant groups. Sleep quality and sleep disturbances improved some in all groups including the group that did not exercise.Based on these findings, interventions focused on resistance exercises may be a new way to promote better sleep and improve cardiovascular health.
“While both aerobic and resistance exercise are important for overall health, our results suggest that resistance exercises may be superior when it comes to getting better ZZZs at night,” Brellenthin said. “Resistance exercise significantly improved sleep duration and sleep efficiency, which are critical indicators of sleep quality that reflects how well a person falls asleep and stays asleep throughout the night. Therefore, if your sleep has gotten noticeably worse over the past two stressful years, consider incorporating two or more resistance exercise training sessions into your regular exercise routine to improve your general muscle and bone health, as well as your sleep.”
A study limitation is the researchers’ use of a self-reported sleep questionnaire to assess sleep rather than objectively monitoring sleep.
Story Source:
Materials provided by American Heart Association. Note: Content may be edited for style and length.

Read more →